Status:

COMPLETED

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Lead Sponsor:

Spanish Breast Cancer Research Group

Collaborating Sponsors:

Novartis

Conditions:

Breast Cancer

Neoplasm Metastasis

Eligibility:

FEMALE

18+ years

Phase:

PHASE4

Brief Summary

The study objective is to evaluate the differences, in terms of first occurrence of a skeletal event, in patients with breast cancer and symptomatic bone metastases, when pamidronate is administered d...

Detailed Description

Background: Pamidronate (PMT) is effective in reducing skeletal related events (SRE) in breast cancer (BC) patients with bone metastasis (BM). Its best way of administration and optimum treatment dura...

Eligibility Criteria

Inclusion

  • Written informed consent.
  • Up to two previous or current hormone therapy treatments for metastatic breast cancer are allowed.
  • Normal or borderline renal function (serum creatinine \< 1.5 x upper normal limit \[UNL\]).
  • Normal calcium levels in serum, or slightly non-symptomatic high levels (\< 1.25 x UNL).
  • Performance status 0, I or II in World Health Organization (WHO) scale.

Exclusion

  • Treatment with bisphosphonates in the 30 previous days, or any time if the indication was treatment of metastatic bone lesions.
  • Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia.
  • Metastases in central nervous system (CNS).
  • Hypersensitivity to bisphosphonates or other components of the formula.
  • Pregnant or lactating women.
  • Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease.

Key Trial Info

Start Date :

October 18 2000

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 4 2004

Estimated Enrollment :

152 Patients enrolled

Trial Details

Trial ID

NCT00128297

Start Date

October 18 2000

End Date

June 4 2004

Last Update

March 28 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Spanish Breast Cancer Research Group (GEICAM)

San Sebastián de los Reyes, Madrid, Spain, 28700